Hemolytic-uremic syndrome secondary prevention: Difference between revisions

Jump to navigation Jump to search
Line 22: Line 22:
  | doi = 10.5049/EBP.2013.11.1.9
  | doi = 10.5049/EBP.2013.11.1.9
  | pmid = 23946760
  | pmid = 23946760
}}</ref>
}}</ref><ref>{{cite journal|doi=10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+}}</ref>


*Supportive therapy and hydration
*Supportive therapy and hydration
*Obsereved closely
*Obsereved closely
*Use eculizumab in aHUS


==References==
==References==

Revision as of 19:24, 17 August 2018

Hemolytic-uremic syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemolytic-uremic syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemolytic-uremic syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemolytic-uremic syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemolytic-uremic syndrome secondary prevention

CDC on Hemolytic-uremic syndrome secondary prevention

Hemolytic-uremic syndrome secondary prevention in the news

Blogs on Hemolytic-uremic syndrome secondary prevention

Directions to Hospitals Treating Hemolytic-uremic syndrome

Risk calculators and risk factors for Hemolytic-uremic syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

Effective measures for the secondary prevention of HUS include:[1][2][3]

  • Supportive therapy and hydration
  • Obsereved closely
  • Use eculizumab in aHUS

References

  1. Grisaru, Silviu (2014). "Management of hemolytic-uremic syndrome in children". International Journal of Nephrology and Renovascular Disease: 231. doi:10.2147/IJNRD.S41837. ISSN 1178-7058.
  2. Hoon Young Choi & Sung Kyu Ha (2013). "Potassium balances in maintenance hemodialysis". Electrolyte & blood pressure : E & BP. 11 (1): 9–16. doi:10.5049/EBP.2013.11.1.9. PMID 23946760. Unknown parameter |month= ignored (help)
  3. . doi:10.1007/s00467-018-4025-0 Share on FacebookShare on TwitterShare on Google+ Check |doi= value (help). Missing or empty |title= (help)

Template:WH Template:WS